Pharmaceutical News

RSS

Medical cannabis can improve appetite, ease chronic pain, say researchers

Though controversial, medical cannabis has been gaining ground as a valid therapy, offering relief to suffers of diseases such as cancer, Post-Traumatic Stress Disorder, ALS and more.

25 Jan 2013

New and efficient process to make popular medication for mental illness

In a demonstration of the power of green chemistry, scientists are reporting development of a new and more efficient process for making one of the most costly and widely used medications for severe mental illness.

25 Jan 2013

Effective therapy needed for chronic fatigue syndrome patients

Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA).

25 Jan 2013

Dr. Reddy's Laboratories introduces Desloratadine ODT in the US market

Dr. Reddy's Laboratories announced today that it has launched Desloratadine ODT (2.5 mg & 5 mg), a bioequivalent generic version of Clarinex® Reditabs® (desloratadine) in the US market on January 24, 2013.

25 Jan 2013

Ibuprofen and naproxen can cause kidney damage in children

Sick children, especially those with some dehydration from flu or other illnesses, risk significant kidney injury if given drugs such as ibuprofen and naproxen, Indiana University School of Medicine researchers said Friday.

25 Jan 2013

NSAIDs cause acute kidney injury in some children

Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, are commonly used to treat pain and reduce fever in children. However, the use of NSAIDs has been shown to cause acute kidney injury (AKI) in some children

25 Jan 2013

Women taking tacrolimus drug can breast feed their babies

Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

24 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Experts meet to discuss U.S., global TB drug shortages

The Center for Global Health Policy's "Science Speaks" blog reports on a meeting held last week "to discuss the problem of U.S. and global tuberculosis [TB] drug shortages."

24 Jan 2013

Indian company plans to make lower-cost injectable polio vaccine

Serum Institute of India Ltd., the world's largest vaccine manufacturer, plans to "slash the price of polio immunization and introduce shots for diarrhea and pneumonia, undercutting Pfizer Inc. and GlaxoSmithKline Plc.," Bloomberg Businessweek reports.

24 Jan 2013

Biomedical engineers identify natural switch that controls breast cancer metastasis

With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body's inflammatory response and how malignant breast cancer cells use the bloodstream to spread.

24 Jan 2013

Inspiration, Ipsen and Baxter enter Asset Purchase Agreement for OBI-1

Ipsen and Inspiration Biopharmaceuticals Inc. today announced they entered into an Asset Purchase Agreement (APA) whereby Baxter International (Baxter) agrees to acquire the worldwide rights to OBI-1, a recombinant porcine factor VIII (rpFVIII) in development for congenital hemophilia A with inhibitors and acquired hemophilia A, and Ipsen's industrial facility in Milford (Boston, MA).

24 Jan 2013

Study may help predict which multiple myeloma patients will respond better to certain treatments

A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.

24 Jan 2013

Study identifies how astrocytes regulate a neurotransmitter involved in sleep

Neuroscience researchers from Tufts University have found that our star-shaped brain cells, called astrocytes, may be responsible for the rapid improvement in mood in depressed patients after acute sleep deprivation. This in vivo study, published in the current issue of Translational Psychiatry, identified how astrocytes regulate a neurotransmitter involved in sleep.

23 Jan 2013

New apatamer can boost therapeutic effect of cell-based vaccines

A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

23 Jan 2013

BH3-mimetics might be new option for treatment of autoimmune conditions

Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune system attacks the body's own tissues.

23 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

23 Jan 2013

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data on PV-10 will be presented in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC.

23 Jan 2013

Actavis seeks FDA approval to market generic Opana ER

Watson Pharmaceuticals, Inc. today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets.

23 Jan 2013